Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 1
Submit an article Journal homepage
182
Views
30
CrossRef citations to date
0
Altmetric
Review

Targeting ischemic brain injury with intravenous immunoglobulin

Thiruma V Arumugam Texas Tech University Health Sciences Center, Department of Pharmaceutical Sciences, School of Pharmacy, Amarillo, Texas 79106, USA +1 806 356 4015 ext 329; +1 806 356 4034; [email protected]
, PhD,
Pradeep K Selvaraj Texas Tech University Health Sciences Center, Department of Pharmaceutical Sciences, School of Pharmacy, Amarillo, Texas 79106, USA +1 806 356 4015 ext 329; +1 806 356 4034; [email protected]
, MD PhD,
Trent M Woodruff School of Biomedical Sciences, University of Queensland, Brisbane, Australia
, PhD &
Mark P Mattson Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, MD 21224, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
, PhD
Pages 19-29 | Published online: 13 Dec 2007

Bibliography

  • Abe Y. Therapeutic application of intravenous human natural immunoglobulin preparation. Front Biosci 1996;1:e26-e33
  • Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev 2004;1:CD000361
  • Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007;26:67-78
  • Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, et al. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs 2002;16:47-55
  • Negi VS, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007;27:233-45
  • Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007;204:11-15
  • Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59:S13-S21
  • Adams HP Jr. Stroke: a vascular pathology with inadequate management. J Hypertens Suppl 2003;21:S3-S7
  • Arumugam TV, Granger DN, Mattson MP. Stroke and T-cells. Neuromolecular Med 2005;7:229-42
  • Mattson MP, Culmsee C, Yu ZF. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res 2000;301:173-87
  • Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-7
  • Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-568
  • Zheng Z, Yenari MA. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 2004;26:884-92
  • Frey JL. Recombinant tissue plasminogen activator (rtPA) for stroke. The perspective at 8 years. Neurologist 2005;11:123-33
  • Ringleb PA, Schellinger PD, Schranz C, et al. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful? Stroke 2002;33:1437-41
  • Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1:36-45
  • Sapan CV, Reisner HM, Lundblad RL. Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics. Vox Sang 2007;92:197-205
  • Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl 2005;11:1469-80
  • Amzel LM, Poljak RJ. Three-dimensional structure of immunoglobulins. Ann Rev Biochem 1979;48:961-97
  • Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006;6:528-34
  • Peakman M, Dayan CM. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology 2001;104:361-6
  • Romagnani S. New therapeutic strategies in allergic diseases. Drugs Today 2003;39:849-65
  • Verhagen J, Blaser K, Akdis CA, et al. Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. Immunol Allergy Clin North Am 2006;26:207-31
  • Kawamura T. Treatment of IgA nephropathy: corticosteroids, tonsillectomy, and mycophenolate mofetil. Contrib Nephrol 2007;157:37-43
  • Ghobrial IM, Leleu X, Hatjiharissi E, et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs 2007;12:155-63
  • Ben-Efraim S, Keisari Y, Ophir R, et al. Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic humoral factor THF-gamma2. Crit Rev Immunol 1999;19:261-84
  • Riker AI, Radfar S, Liu S, et al. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 2007;7:345-58
  • Eibl MM, Wedgwood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989;1(Suppl):1-42
  • Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm 1990;9:509-29
  • Simon HU, Spath PJ. IVIG–mechanisms of action. Allergy 2003;58:543-52
  • Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura – current management practices. Expert Opin Pharmacother 2004;5:2515-27
  • Satou GM, Giamelli J, Gewitz MH. Kawasaki disease: diagnosis, management, and long-term implications. Cardiol Rev 2007;15:163-9
  • Durandy A, wahn V, Petteway S, et al. Immunoglobulin replacement therapy in primary antibody deficiency diseases–maximizing success. Int Arch Allergy Immunol 2005;136:217-29
  • Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 2007;3:262-72
  • Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006;5:153-5
  • Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology–therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007;3:36-44
  • Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004;5:153-60
  • Carp HJ, Sapir T, Shoenfeld Y. Intravenous immunoglobulin and recurrent pregnancy loss. Clin Rev Allergy Immunol 2005;29:327-32
  • Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005;42:839-48
  • Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366:1653-66
  • Nobile-Orazio E, Terenghi F. IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. J Neurol 2005;252(Suppl 1):I7-I23
  • Van Schaik IN, Van den Berg LH, De Haan R, et al. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005;2:CD004429
  • Latremouille C, Genevaz D, Hu MC, et al. Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab’)2-mediated anti-complement activity. Clin Exp Immunol 1997;110:122-6
  • Stangel M, Compston A, Scolding NJ. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (“IVIg”). J Neuroimmunol 2000;103:195-201
  • Clynes R. Immune complexes as therapy for autoimmunity. J Clin Invest 2005;115:25-7
  • Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 2005;29:185-99
  • Ibanez C, Montoro-Ronsano JB. Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. Curr Pharm Biotechnol 2003;4:239-47
  • Ephrem A, Misra N, Hassan G, et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med 2005;5:135-40
  • Janke AD, Giuliani F, Yong VW. IVIg attenuates T cell-mediated killing of human neurons. J Neuroimmunol 2006;177:181-8
  • Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3
  • Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161:3781-90
  • Terenghi F, Allaria S, Nobile-Orazio E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 2006;11:67-71
  • Zhu KY, Feferman T, Maiti PK, et al. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol 2006;176:187-97
  • Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999;116:509-15
  • Andersson UG, Bjork L, Skansen-Saphir U, et al. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 1993;79:211-16
  • Toungouz M, Denys CH, De Groote D, et al. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995;89:698-703
  • Andersson J, Skansen-Saphir U, Sparrelid E, et al. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996;104(Suppl 1):10-20
  • Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001;108(4 Suppl):S95-S98
  • Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006;12:688-92
  • Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003;92:1206-15
  • Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-35
  • Basta M, Van Goor F, Luccioli S, et al. F(ab)’2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003;9:431-8
  • Vivanco F, Munoz E, Vidarte L, et al. The covalent interaction of C3 with IgG immune complexes. Mol Immunol 1999;36:843-52
  • Lutz HU, Stammler P, Bianchi V, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004;103:465-72
  • Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991;77:376-80
  • Crow AR, Song S, Semple JW, et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 2007;109:155-8
  • Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994;139:71-8
  • Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-90
  • Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 1992;39:74-7
  • Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-72
  • Caccavelli L, Field AC, Betin V, et al. Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells. Eur J Immunol 2001;31:2781-90
  • Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. J Rheumatol 1993;20:2176-7
  • Rigal D, Vermot-Desroches C, Heitz S, et al. Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994;71:309-14
  • Abe Y, Horiuchi A, Miyake M, et al. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19
  • Huang JL, Lee WY, Chen LC, et al. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000;84:345-52
  • Gill V, Doig C, Knight D, et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005;112:2031-9
  • Lapointe BM, Herx LM, Gill V, et al. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004;127:2649-56
  • Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 2003;3:65-94
  • Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004;61:657-68
  • Mattson MP. Neuroprotective signal transduction: relevance to stroke. Neurosci Biobehav Rev 1997;21:193-206
  • Love S. Oxidative stress in brain ischemia. Brain Pathol 1999;9:119-31
  • Tang SC, Arumugam TV, Cutler RG, et al. Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem 2007;101:729-36
  • Okun E, Arumugam TV, Tang SC, et al. The organotellurium compound ammonium trichloro(dioxoethylene-0,0′) tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. J Neurochem 2007;102:1232-41
  • Neumar RW. Molecular mechanisms of ischemic neuronal injury. Ann Emerg Med 2000;36:483-506
  • Hall ED. Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci 1995;134(Suppl):79-83
  • Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998;56:149-71
  • Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog Brain Res 1998;118:215-29
  • Ishikawa M, Zhang JH, Nanda A, et al. Inflammatory responses to ischemia and reperfusion in the cerebral microcirculation. Front Biosci 2004;9:1339-47
  • Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007;184:53-68
  • Lai AY, Todd KG. Microglia in cerebral ischemia: molecular actions and interactions. Can J Physiol Pharmacol 2006;84:49-59
  • Seifert G, Schilling K, Steinhauser C. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci 2006;7:194-206
  • Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 2004;19:151-67
  • Del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. Thromb Res 2000;98:73-81
  • Yilmaz G, Arumugam TV, Stokes KY, et al. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006;113:2105-12
  • Arumugam TV, Shiels IA, Woodruff TM, et al. The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-9
  • Arumugam TV, Magnus T, Woodruff TM, et al. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 2006;374:33-45
  • Vasthare US, Barone FC, Sarau HM, et al. Complement depletion improves neurological function in cerebral ischemia. Brain Res Bull 1998;45:413-19
  • Figueroa E, Gordon LE, Feldhoff PW, et al. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett 2005;380:48-53
  • De Simoni MG, Rossi E, Storini C, et al. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol 2004;164:1857-63
  • Heimann A, Takeshima T, Horstick G, et al. C1-esterase inhibitor reduces infarct volume after cortical vein occlusion. Brain Res 1999;838:210-13
  • Storini C, Rossi E, Marrella V, et al. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2005;19:10-17
  • Huang J, Kim LJ, Mealey R, et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999;285:595-9
  • Mocco J, Mack WJ, Ducruet AF, et al. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J Neurosurg 2006;105:595-601
  • Mocco J, Mack WJ, Ducruet AF, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 2006;99:209-17
  • Arumugam TV, Tang SC, Lathia JD, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2007;104:14104-9
  • Finch AM, Vogen SM, Sherman SA, et al. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J Med Chem 1997;40:877-84
  • Kohl J, Wills-Karp M. Complement regulates inhalation tolerance at the dendritic cell/T cell interface. Mol Immunol 2007;44:44-56
  • Guo RF, Ward PA. Role of C5a in inflammatory responses. Ann Rev Immunol 2005;23:821-52
  • Guo RF, Ward PA. Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radic Biol Med 2002;33:303-10
  • Arumugam TV, Salter JW, Chidlow JH, et al. Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol 2004;287:H2555-H2560
  • Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003;62:127-36
  • Stangel M, Compston A. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J Neuroimmunol 2001;112:63-71
  • White DA, Leonard MC. Acute stroke with high-dose intravenous immune globulin. Am J Health Syst Pharm 2007;64:1611-4
  • Marie I, Maurey G, Herve F, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714-21

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.